Anti-tumor effects of recombinant human cyclophilin A combined with immune checkpoint inhibitors in the experimental model of melanoma B16 in vivo
Introduction. Immune checkpoint inhibitors have an exceptional position in cancer immunotherapy. Currently, anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) and anti-PD-1/PD-L1 (PD-1 – programmed cell death 1, PD-L1 – programmed death 1 ligand 1) therapies are most widely applied in clinica...
Saved in:
Main Authors: | A. A. Kalinina, D. B. Kazansky, L. M. Khromykh |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2024-10-01
|
Series: | Успехи молекулярной онкологии |
Subjects: | |
Online Access: | https://umo.abvpress.ru/jour/article/view/710 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CYCLOPHILIN A: STRUCTURE AND FUNCTIONS
by: A. A. Kalinina, et al.
Published: (2017-12-01) -
Soluble expression of recombinant cyclophilin A in Escherichia coli
by: YAN Xiao, et al.
Published: (2010-07-01) -
A Delayed Presentation of Immune Checkpoint Inhibitor Colitis
by: Alicia Nahhas, et al.
Published: (2025-06-01) -
Immune Checkpoint Inhibitors in Melanoma Treatment: Advances and Obstacles
by: A. V. Sultanbaev
Published: (2025-04-01) -
The role of immunotherapy in the treatment of skin melanoma: a contemporary perspective
by: P. S. Masaeva
Published: (2024-06-01)